By Fineline Cube 
Hong Kong WinHealth Pharma Group announced that China’s National Medical Products Administration (NMPA) has granted market approval for Korsuva (difelikefalin), a first-in-class therapy indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adult patients undergoing hemodialysis.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full market approval |
| Product | Korsuva (difelikefalin) injection |
| Indication | Moderate-to-severe CKD-associated pruritus in adult hemodialysis patients |
| Approval Date | 17 Apr 2026 |
| Commercial Rights | Exclusive rights held by WinHealth Pharma under a December 2022 licensing agreement |
Drug Profile & Mechanism of Action
- Molecule: Difelikefalin, a hydrophilic peptide
- Target: Peripheral kappa opioid receptor (KOR) agonist
- Innovation: Addresses the core pathogenesis of CKD-aP by correcting the imbalance between mu and kappa opioid receptor activity, leading to a reduction in key inflammatory markers.
- CNS Safety: Its hydrophilic structure prevents crossing of the blood-brain barrier, eliminating risks of addiction and central nervous system (CNS) side effects like insomnia or constipation. It is not a controlled substance.
Clinical & Commercial Context
- Global Status: Difelikefalin, originally developed by US-based Cara Therapeutics, Inc., is already approved and marketed in the United States, European Union, United Kingdom, Canada, Switzerland, Singapore, Australia, and Japan for the same indication.
- Acquisition: The global rights were acquired by Swiss firm Vifor Fresenius Medical Care Renal Pharma in April 2025.
- Chinese Partnership: WinHealth Pharma secured exclusive development and commercialization rights for the Greater China region through a strategic licensing deal with Vifor Fresenius Medical Care in December 2022.
- Market Opportunity: CKD-aP is a debilitating condition affecting a significant portion of the estimated 800,000+ hemodialysis patients in China, representing a substantial unmet medical need and a high-value commercial opportunity.
This approval marks a significant milestone for WinHealth Pharma, positioning it as a key player in the nephrology therapeutic space within China and offering a novel, non-addictive treatment option for a patient population with limited alternatives.
Forward-Looking Statements
This brief contains forward-looking statements regarding the commercial launch and market impact of Korsuva in China. Actual results may be influenced by factors including market access, pricing negotiations, and competitive dynamics.-Fineline Info & Tech